Reldesemtiv – Kodiac biolabs

Our opinion on this compoundNiche research probe

60/100

Phase 3 futility in ALS leaves a well-characterized FSTA with real probe value but no clinical future

Look, reldesemtiv is one of those compounds where the science is genuinely interesting and the clinical story is genuinely disappointing. The fast skeletal muscle troponin activator class was a real idea. Sensitize the sarcomere to calcium by slowing troponin C release, get more force output from whatever motor units are still firing in a denervated muscle. That’s a clean mechanistic hypothesis, and Cytokinetics executed the chemistry well enough to confirm it in actual human tissue.

The Phase 1 pharmacodynamic work is the bright spot. Sixteen healthy volunteers, tibialis anterior force-frequency response amplified roughly 60 percent at 10 Hz stimulation. That’s not an indirect surrogate; that’s the mechanism working in human muscle. The pharmacokinetics are well-characterized across five Phase 1 studies, dose-proportional exposure, 5-14 hour half-life, similar profiles in young and elderly. If you want to study calcium sensitization in fast skeletal fibers, this compound is pharmacologically tractable and well-understood at the bench level.

The second-generation story also matters. Tirasemtiv, the first FSTA, hit dose-limiting dizziness, nausea, weight loss, and insomnia hard enough that 34.2 percent of VITALITY-ALS participants discontinued. Reldesemtiv represents property-based optimization that genuinely improved tolerability. Thats a real accomplishment even if it didn’t change the terminal clinical outcome. The selectivity profile is also authentic: no activation of slow skeletal or cardiac troponin complexes, which is exactly what you want from a probe compound designed to isolate fast-fiber effects.

But COURAGE-ALS happened. Phase 3, 486 patients, 83 centers across 16 countries, 24 weeks. Conditional power at the second interim analysis: 8.4 percent. The primary ALSFRS-R endpoint numerically favored placebo. No preplanned subgroup favored reldesemtiv. The program was terminated for futility. That’s not ambiguous. The translational hypothesis that calcium sensitization of residual fast fibers would slow functional decline in ALS did not survive a rigorous test. The FORTITUDE-ALS Phase 2 miss on slow vital capacity (p=0.11) was a warning sign; COURAGE-ALS confirmed it.

The SMA Phase 2 data is more interesting and prevents a complete write-off. Seventy patients, statistically significant improvement in six-minute walk distance at week 4 (35.6 m, p=0.0037) and maximum expiratory pressure at week 8 in the 450 mg group. The neuronal-attenuation hypothesis may hold better in SMA than ALS for reasons related to the pattern of motor neuron loss and the stage at which fast-fiber populations are still available to sensitize. Whether that Phase 2 signal survives a larger trial is genuinely unknown.

What we think: reldesemtiv earns real points for mechanism novelty, fast-fiber selectivity, and the quality of its clinical evidence base, even though that evidence base ultimately killed the program. It’s now probe territory. For investigators studying calcium handling in fast skeletal muscle, motor unit physiology, or the FSTA class itself, this is the best-characterized compound available. The WADA listing confirms sourcing exists. Score it for what it is now: a well-made tool with a closed clinical chapter.

Novelty: 62
Mechanism promise: 68
In-category differentiation: 65
Evidence quality: 65
Translational signal: 38
Research bench value: 58

Rationale Reldesemtiv scores well on mechanism novelty and fast-fiber selectivity but takes a decisive translational hit from COURAGE-ALS, where conditional power fell to 8.4 percent and the primary endpoint numerically favored placebo; the SMA Phase 2 signal and clean pharmacological profile sustain moderate bench utility. Category placement as niche-probe reflects a terminated clinical program that left behind the best-available FSTA tool compound for fast skeletal muscle calcium biology.

Second-generation fast skeletal muscle troponin activator (FSTA) selective for fast skeletal muscle fibers

A next-generation fast skeletal muscle troponin activator developed by Cytokinetics to amplify skeletal muscle force output through calcium sensitization of the sarcomere, evaluated in Phase 2 and Phase 3 clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy.

Abstract

Reldesemtiv (CK-2127107) is a small-molecule fast skeletal muscle troponin activator (FSTA) that selectively binds the regulatory troponin complex in fast skeletal muscle fibers, slows the rate of calcium release from troponin C, and thereby sensitizes the sarcomere to calcium at submaximal stimulation frequencies. The compound was discovered at Cytokinetics, Inc. through property-based optimization of a high-throughput screening hit, yielding improved free exposure, in vivo muscle activation potency, and tolerability relative to the first-generation FSTA tirasemtiv, which had failed the Phase 3 VITALITY-ALS trial primarily because of dose-limiting tolerability (dizziness, nausea, weight loss, insomnia) and a 34.2 percent treatment discontinuation rate. Reldesemtiv does not activate slow skeletal or cardiac troponin complexes, providing a selectivity basis for its intended use in conditions characterized by fast skeletal muscle weakness secondary to attenuated neuronal input, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and chronic obstructive pulmonary disease. In a Phase 1 pharmacodynamic study in 16 healthy volunteers, reldesemtiv amplified the tibialis anterior force-frequency response by approximately 60 percent at 10 Hz nerve stimulation at the highest plasma concentrations tested, confirming the mechanism of action in human skeletal muscle. Pharmacokinetics across five Phase 1 studies demonstrated dose-proportional exposure with a terminal half-life of approximately 5 to 14 hours depending on dose, a time to peak concentration of 2 to 3 hours, and similar pharmacokinetic profiles in young and elderly subjects. The Phase 2 FORTITUDE-ALS trial (n=458; 12 weeks; placebo, 150, 300, or 450 mg twice daily) did not reach statistical significance on its primary endpoint of slow vital capacity change (p=0.11), though trends favoring reldesemtiv were observed across all three endpoints and a post hoc analysis of the ALSFRS-R functional scale reached nominal significance (p=0.01). The Phase 2 SMA study (n=70; 8 weeks; 150 or 450 mg twice daily) reported statistically significant improvement in six-minute walk distance at week 4 (35.6 m, p=0.0037) and maximum expiratory pressure at week 8 (13.2 cmH2O, p=0.03) in the 450 mg group, with concentration-response relationships in the highest plasma concentration quartile reaching significance on both endpoints. The Phase 3 COURAGE-ALS trial (n=486; 24 weeks; 300 mg twice daily versus placebo; 83 centers in 16 countries) was terminated for futility at the second planned interim analysis when conditional power for the primary endpoint (ALSFRS-R score change at 24 weeks) was 8.4 percent. The primary analysis showed a mean difference of negative 1.1 points (95 percent CI, negative 2.17 to negative 0.08; p=0.04), numerically favoring placebo. No preplanned subgroup favored reldesemtiv. The compound is not approved by any regulatory authority for any indication. This monograph reviews the chemistry, discovery, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, adverse events, and a comparative assessment of reldesemtiv against tirasemtiv, tofersen, riluzole, edaravone, and risdiplam on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1658Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.